Pathfinder Cell Therapy, Inc.

CIK:0000889428|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating expenses:
Research and development	$ 71	$ 26	$ 111	$ 209
General and administrative	$ 138	$ 187	$ 446	687
Sales and marketing				5
Operating expenses	$ 209	$ 213	$ 557	901
Loss from operations before other expense	(209)	(213)	(557)	(901)
Other expense:
Interest expense	(80)	(71)	(230)	(200)
Net loss	$ (289)	$ (284)	$ (787)	$ (1,101)
Net loss per common share-basic and diluted	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted average shares outstanding	667,161	667,161	667,161	667,161

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (787)	$ (1,101)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	$ 3	3
Stock based compensation relating to options		2
Changes in operating assets and liabilities:
Decrease in prepaid expenses	$ 42	61
Increase (decrease) in accounts payable	97	(2)
Increase in accrued expenses	193	201
Net cash used in operating activities	(452)	(836)
Cash flows from financing activities:
Payments of insurance note payable	(34)	(45)
Proceeds from convertible notes payable	464	860
Net cash provided by financing activities	430	815
Net decrease in cash	(22)	(21)
Cash at beginning of period	26	44
Cash at end of period	$ 4	$ 23

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 4	$ 26
Prepaid expenses	5	47
Total current assets	9	73
Intangible, net of accumulated amortization	30	33
TOTAL	39	106
Current liabilities:
Accounts payable	326	229
Accrued expenses (including related party amount of $509 and $385, respectively)	$ 1,030	837
Insurance note payable		34
Note payable - Clubb Capital	$ 244	244
Convertible notes payable (including related party amount of $2,799 and $2,465, respectively)	5,169	4,705
Total current liabilities	$ 6,769	$ 6,049
Commitments and other matters (Note G)
Capital deficit:
Preferred stock, $.01 par value; shares authorized - 5,000; issued and outstanding - none
Common stock, $.001 par value; shares authorized - 1,000,000; issued and outstanding - 667,161 at September 30, 2015 and December 31, 2014, respectively	$ 667	$ 667
Additional paid-in capital	11,830	11,830
Accumulated deficit	(19,227)	(18,440)
Total capital deficit	(6,730)	(5,943)
TOTAL	$ 39	$ 106